Alligator Bioscience 将来の成長

Future 基準チェック /56

Alligator Bioscienceは、51.7%と55.6%でそれぞれ年率51.7%で利益と収益が成長すると予測される一方、EPSはgrowで7%年率。

主要情報

51.7%

収益成長率

7.0%

EPS成長率

Biotechs 収益成長	37.3%
収益成長率	55.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	14 Jun 2023

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

BATS-CHIXE:ATORXS - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	85	-162	N/A	-149	1
12/31/2024	367	149	N/A	166	2
12/31/2023	79	-146	N/A	-188	3
3/31/2023	40	-213	-178	-177	N/A
12/31/2022	36	-193	-173	-173	N/A
9/30/2022	21	-177	-163	-162	N/A
6/30/2022	20	-163	-149	-148	N/A
3/31/2022	18	-152	-139	-139	N/A
12/31/2021	13	-142	-127	-127	N/A
9/30/2021	8	-139	-125	-125	N/A
6/30/2021	5	-133	-128	-128	N/A
3/31/2021	6	-133	-127	-127	N/A
12/31/2020	6	-143	-141	-141	N/A
9/30/2020	5	-169	-161	-160	N/A
6/30/2020	9	-194	-187	-185	N/A
3/31/2020	4	-209	-199	-197	N/A
12/31/2019	4	-210	-183	-181	N/A
9/30/2019	30	-181	-174	-172	N/A
6/30/2019	26	-164	-156	-154	N/A
3/31/2019	26	-152	-144	-141	N/A
12/31/2018	27	-150	-112	-104	N/A
9/30/2018	53	-107	-112	-97	N/A
6/30/2018	54	-93	-97	-80	N/A
3/31/2018	55	-86	-89	-71	N/A
12/31/2017	57	-64	-114	-100	N/A
9/30/2017	12	-96	-87	-80	N/A
6/30/2017	15	-77	-80	-76	N/A
3/31/2017	18	-91	-44	-41	N/A
12/31/2016	59	-48	N/A	-38	N/A
9/30/2016	55	-68	N/A	-52	N/A
12/31/2015	292	207	N/A	205	N/A
12/31/2014	1	-77	N/A	-63	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ATORXSは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 1.2% ) よりも高い成長率であると考えられます。

収益対市場: ATORXS今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: ATORXS今後 3 年以内に収益を上げることが予想されます。

収益対市場: ATORXSの収益 ( 55.6% ) UK市場 ( 3.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: ATORXSの収益 ( 55.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ATORXSの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Alligator Bioscience 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Recent updates

Alligator Bioscience AB (publ), Annual General Meeting, May 07, 2025

Alligator Bioscience AB (Publ) Appoints Nomination Committee in Respect of AGM 2025

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Alligator Bioscience AB (publ) and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV- 527 Monotherapy in Multiple Solid Tumor Types At ESMO Congress 2024

Alligator Bioscience AB (Publ) Appoints Johan Giléus as Chief Financial Officer as of August 12, 2024

Alligator Bioscience Announces Completion of Enrollment in Mitazalimab Optimize-1 Study

Alligator Bioscience Announces Results from the Ongoing Optimize-1 Trial

Alligator Bioscience AB (publ) to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024

Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting

Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer

Alligator Bioscience AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Alligator Bioscience AB (Publ) Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Alligator Bioscience Plans to Adjust Size of Organization with Reduction of Approximately 20% to 25% of Current Workforce

Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

Alligator Bioscience AB (Publ) Appoints Bertil Brinck as Chairman of the Nomination Committee

Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab

Alligator Bioscience AB (publ) Announces Resignation of Malin Carlsson as Chief Operating Officer At the End of October

Alligator Bioscience AB (Publ) Announces Executive Changes

Alligator Bioscience AB (publ) Announces Phase II Results Indicate Durability of Response for Alligator's CD40 Agonist

Alligator Bioscience Announces Positive Second Interim Results from the Ongoing Optimize-1 Phase 2 Study of the Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

Alligator Bioscience to Present Latest Clinical Data from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer At Asco Annual Meeting 2023

Full year 2022 earnings released: kr0.88 loss per share (vs kr1.58 loss in FY 2021)

High number of new directors

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘